Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Status:
Completed
Trial end date:
2015-05-28
Target enrollment:
Participant gender:
Summary
Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT)
in male and female participants with Fabry disease who are currently receiving ERT and who
have an alpha galactosidase-A (α Gal-A) mutation that is amenable to migalastat, based on the
clinical trial human embryonic kidney cell (HEK) assay.